Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: A subanalysis of the EPIC study of deferasirox

by Vip Viprakasit, Hishamshah Ibrahim, Shau Yin Ha, Phoebe Joy Ho, Chi Kong Li, Lee Lee Chan, Chang Fang Chiu, Pranee Sutcharitchan, Dany Habr, Gabor Domokos, Bernard Roubert, Hong Ling Xue, Donald K. Bowden, Kai Hsin Lin
Published 2018

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major

by Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen S. Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher
Published 2018

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

by Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher
Published 2018